James N. Topper, Director at Phathom Pharmaceuticals, Inc. (PHAT), bought 3,780 shares at $3.86 ($15K) on 2025-05-21, disclosed to the SEC on 2025-05-23.
Open-market purchase of $15k PHAT by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Something here stands out, but not much.
| Filing → |
| NAMS | BUY | 2025-08-13 | $11K | — | Filing → |
| NAMS | BUY | 2025-06-26 | $69K | — | Filing → |
| NAMS | BUY | 2025-06-18 | $167K | — | Filing → |